PVLA NASDAQ
Palvella Therapeutics, Inc.
1W: +7.2%
1M: -5.0%
3M: -6.8%
YTD: +32.5%
1Y: +82.1%
3Y: +541.5%
5Y: -62.3%
$132.91
+6.68 (+5.29%)
Weekly Expected Move ±6.6%
$109
$117
$125
$133
$142
Credit Risk of going bust: lower than 83% of companies Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.01 (down more than 99.9%), Palvella Therapeutics, Inc. would be worth roughly what it owes.
Total debt $535K against a stock market value of $1.92B.
Distance to default 10.67 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $268K (short-term plus half of long-term), stock volatility 80.6%; Altman Z'' 8.64. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.01 (down more than 99.9%), Palvella Therapeutics, Inc. would be worth roughly what it owes.
Total debt $535K against a stock market value of $1.92B.
Distance to default 10.67 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $268K (short-term plus half of long-term), stock volatility 80.6%; Altman Z'' 8.64. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.9B
52W Range68.96-161.38
Volume178,757
Avg Volume233,424
Beta-0.17
Dividend—
Analyst Ratings
Company Info
CEOWesley H. Kaupinen
Employees29
SectorHealthcare
IndustryBiotechnology
IPO Date2015-01-02
Websitepalvellatx.com
353 W. Lancaster Avenue
Wayne, PA 19087
US
Wayne, PA 19087
US
484 253 1461
About Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
Latest News
Palvella Therapeutics (NASDAQ:PVLA) COO Sells $537,313.54 in Stock
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Stock Has Consensus Target Price of $209.79
Oppenheimer's fall 2026 SMID-cap ideas include four Strong Buy stocks
U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
3,600 Shares in Palvella Therapeutics, Inc. $PVLA Acquired by Jupiter Topco LLC
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Goin Kathleen | S-Sale | 2,043 | $123.62 | 2026-10-21 |
| Goin Kathleen | S-Sale | 1,663 | $125.16 | 2026-10-21 |
| Goin Kathleen | S-Sale | 607 | $126.19 | 2026-10-21 |
| JENKINS GEORGE M | S-Sale | 476 | $121.14 | 2026-10-14 |
| JENKINS GEORGE M | S-Sale | 2,072 | $122.62 | 2026-10-14 |